Skip to main content

Welldoc Names Former U.S. CTO, WHO Policy Expert, and Life Sciences Veteran as Strategic Advisors

Aneesh Chopra, Dr. Rajendra Gupta, and Sean Murphy to Accelerate Next Era of the Company’s AI- powered Healthcare

Welldoc®, a leader in AI-powered cardiometabolic health solutions, today announced the appointment of Aneesh Chopra, Dr. Rajendra Gupta, and Sean Murphy as strategic advisors. The new advisors will leverage their deep expertise in technology transformation, public policy, global health, and corporate growth to guide Welldoc’s strategic initiatives and market expansion in support of the company’s mission to empower better cardiometabolic health through AI-powered, personalized digital technology.

“We are at an inflection point with AI powered health solutions, where policy, technology, and corporate execution must align to deliver true transformation,” said Kevin McRaith, President and CEO of Welldoc. “The addition of Mr. Chopra, Dr. Gupta, and Mr. Murphy brings an unparalleled combination of experience. Mr. Chopra offers strategic foresight into U.S. health data and technology policy. Dr. Gupta provides critical insight into global health policy and expansion, particularly in emerging markets. And Mr. Murphy brings a proven track record of scaling high-growth life science companies. Their guidance will be invaluable as we continue to evolve our platform and expand our impact worldwide.”

Biographical Highlights of New Strategic Advisors

Aneesh Chopra

Aneesh Chopra is a recognized leader in U.S. technology and health data policy. He is the Chief Strategy Officer of Arcadia, a leading health data platform that acquired CareJourney, which he co-founded in 2014 to help healthcare organizations manage patient populations. Chopra is best known for his service as the first U.S. Chief Technology Officer (2009–2012), appointed by President Barack Obama, where he spearheaded initiatives to promote health information technology adoption and data sharing. He is the author of the best-selling book, “Innovative State: How New Technologies Can Transform Government”. Mr. Chopra holds a master’s degree in public policy from the Harvard Kennedy School and a bachelor’s degree from Johns Hopkins University. Prior to his government roles, Chopra was a Managing Director at The Advisory Board Company.

Dr. Rajendra Gupta

Dr. Rajendra Pratap Gupta is a highly influential public policy expert and global authority on digital health strategy. He has contributed to policymaking for over two decades and was nominated to the Global Agenda Council of the World Economic Forum in recognition of his work. He served as the former Advisor to the Health Minister of India and played a pivotal role in drafting major national policies, including the National Health Policy 2017 and the National Education Policy. Dr. Gupta is on the Global Roster of Experts for Digital Health and a Member of the Guidelines Development Group at the World Health Organization (WHO). He is also the founder of HIMSS India, the Disease Management Association of India, and the Health Parliament. Additionally, Dr. Gupta authored five best-selling books, including “Healthcare Reforms in India – Making up for the Lost Decades” and “Digital Health – Truly Transformational”. He has been recognized by many global organizations including the United Nations, UNESCO, World Bank, and the Governments of Japan and India, for insights on digital health.

Sean Murphy

Sean Murphy is an accomplished corporate executive with extensive experience in life sciences, corporate finance, business development, and strategic leadership. He spent over 30 years at Abbott Laboratories, where he held various leadership positions, including Head of Corporate M&A and Business Development. He also served as an Executive Vice President at Malin PLC and was a co-founder of the life sciences investment firm Malin. Mr. Murphy is an active Board Member for numerous high-growth and established health technology, biotech, and life science companies, including his current roles at Prenosis and Xenex Disinfection Services. His expertise in mergers and acquisitions, manufacturing, global corporate strategy, and private equity provides Welldoc with crucial insights for commercial scaling and financial rigor as the company enters new market phases.

About Welldoc

Welldoc® is an AI-powered health technology leader committed to connecting people to better, more personalized cardiometabolic care. The company's digital health platform delivers a unified experience for individuals managing diabetes, obesity (including GLP-1 support), hypertension, heart failure, and complex comorbidities including diabetes in pregnancy, sleep apnea, chronic kidney disease (CKD), and metabolic dysfunction-associated steatohepatitis (MASH).

The foundation of Welldoc's solution is healthcare-ready AI—a purpose-built engine grounded in unmatched clinical rigor, with 11 FDA clearances, 60 patents, and more than 100 peer-reviewed publications demonstrating clinical effectiveness and safety. The platform's architecture allows individuals to connect to over 400 device and data sources, while also integrating seamlessly with electronic health record (EHR) systems to enable comprehensive data interoperability across care settings.

Welldoc partners across multiple healthcare sectors—including life sciences companies, health plans, health systems, and employers—to drive innovative health programs, improved patient outcomes, and reduced costs at scale. The company has been recognized as a leader in healthcare innovation, named one of TIME and Statista's World's Top HealthTech Companies and awarded "Best Overall Digital Health Company" by MedTech Breakthrough™ for multiple consecutive years. For more information, visit www.welldoc.com.

Contacts

Recent Quotes

View More
Symbol Price Change (%)
AMZN  222.56
+0.02 (0.01%)
AAPL  274.61
+0.50 (0.18%)
AMD  209.17
+1.59 (0.77%)
BAC  54.81
-0.52 (-0.94%)
GOOG  307.73
-1.59 (-0.51%)
META  657.15
+9.64 (1.49%)
MSFT  476.39
+1.57 (0.33%)
NVDA  177.72
+1.43 (0.81%)
ORCL  188.65
+3.73 (2.02%)
TSLA  489.88
+14.57 (3.07%)
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.